scholarly journals Indications for β‐Blocker Prescriptions in Heart Failure with Preserved Ejection Fraction

2019 ◽  
Vol 67 (7) ◽  
pp. 1461-1466 ◽  
Author(s):  
Brian Yum ◽  
Alexi Archambault ◽  
Emily B. Levitan ◽  
Tina Dharamdasani ◽  
Jerard Kneifati‐Hayek ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Preserved Ejection Fraction ◽  
Β Blocker

scholarly journals Effect of β-Blocker Withdrawal on Functional Capacity in Heart Failure and Preserved Ejection Fraction

2021 ◽  
Vol 78 (21) ◽  
pp. 2042-2056 ◽  
Author(s):  
Patricia Palau ◽  
Julia Seller ◽  
Eloy Domínguez ◽  
Clara Sastre ◽  
Jose María Ramón ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Functional Capacity ◽  
Preserved Ejection Fraction ◽  
Β Blocker

Myocardial Strain for Identification of β-Blocker Responders in Heart Failure with Preserved Ejection Fraction

2019 ◽  
Vol 32 (11) ◽  
pp. 1462-1469.e8 ◽  
Author(s):  
Jin Joo Park ◽  
Hong-Mi Choi ◽  
In-Chang Hwang ◽  
Jun-Bean Park ◽  
Jae-Hyeong Park ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Myocardial Strain ◽  
Preserved Ejection Fraction ◽  
Β Blocker

Acute heart failure with preserved ejection fraction and long-term Readmisions

2008 ◽  
Vol 7 ◽  
pp. 62-63
Author(s):  
J NUNEZ ◽  
L MAINAR ◽  
G MINANA ◽  
R ROBLES ◽  
J SANCHIS ◽  
...  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Acute Heart Failure ◽  
Preserved Ejection Fraction

Galectin-3 in Heart Failure – Linking Fibrosis, Remodelling and Progression

2010 ◽  
Vol 6 (2) ◽  
pp. 33 ◽  
Author(s):  
Christopher R deFilippi ◽  
G Michael Felker ◽  
◽  
Keyword(s):  
Heart Failure ◽  
Ejection Fraction ◽  
Risk Stratification ◽  
Cardiac Fibrosis ◽  
The Elderly ◽  
Preserved Ejection Fraction ◽  
Heart Failure Patients ◽  
Large Populations ◽  
Galectin 3

For many with heart failure, including the elderly and those with a preserved ejection fraction, both risk stratification and treatment are challenging. For these large populations and others there is increasing recognition of the role of cardiac fibrosis in the pathophysiology of heart failure. Galectin-3 is a novel biomarker of fibrosis and cardiac remodelling that represents an intriguing link between inflammation and fibrosis. In this article we review the biology of galectin-3, recent clinical research and its application in the management of heart failure patients.

Sign in / Sign up

Export Citation Format

Share Document